MedTrace Logo

A Correlative Study of Biomarkers of Resistance in Patients With Castrate Resistant Prostate Cancer Treated With Abiraterone

NCT01857908 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2015-06-22

No results posted yet for this study

Summary

Adrenal androgens are serum biomarkers of interest that may help guide abiraterone acetate treatment, particularly at the time of progression. Biomarkers may also help identify pathways to resistance of abiraterone acetate treatment. The most practical way of approaching this question is to explore surrogate biomarkers of prostate cancer including quantification of pharmacodynamic endocrine biomarkers.

Conditions

  • Prostate Cancer (Adenocarcinoma)

Sponsors & Collaborators

  • University Health Network, Toronto

    lead OTHER

Principal Investigators

  • Anthony Joshua, BSc(Med) MBBS PhD FRACP · Princess Margaret Cancer Centre

  • Bernie Eigl, MD · British Columbia Cancer Agency

Eligibility

Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-30
Primary Completion
2014-11-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01857908 on ClinicalTrials.gov